EUVIMEDEUVIMED entdecken
Crossref

Targeting Periplakin of Novel Benzenesulfonamides as Highly Selective Agonists for the Treatment of Vitiligo

Hui Zhong, Panpan Li, Qiuming Yan, Yu Xia, Xin Zhang, Yifan Lai, Liqiang Li, Feifei Wang, Jing Shang, Xiaoming Zha iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hui Zhong und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Vitiligo, Sulfonamides, Benzenesulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Government of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is the most common cause of depigmentation worldwide, with immunosuppressive treatments often being inefficient and prone to recurrence, making it essential to identify new therapeutic targets. Periplakin (PPL) has been identified and confirmed as a key factor in vitiligo-related depigmentation. Based on this, a series of selective PPL agonists, specifically benzenesulfonamides, have been developed. Among these, compound I-3 exhibits superior efficacy compared to ruxolitinib, the only FDA-approved treatment for vitiligo. I-3 has been shown to increase cAMP levels by regulating PPL, which enhances MITF expression, a key transcription factor in melanin biosynthesis. Additionally, I-3 promotes melanin production by regulating tryptophan metabolism. In summary, PPL is a promising drug target, and I-3 has strong potential for future treatment of vitiligo due to its high selectivity and favorable druggability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoSulfonamidesBenzenesulfonamidesHumansAnimalsMiceStructure-Activity RelationshipMelanins

Substanzen

SulfonamidesBenzenesulfonamidesMelanins

Autor:innen und Institutionen

  • School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • School of Engineering, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Xiaoming Zha

Förderung

  • Government of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhong, H., Li, P., Yan, Q., Xia, Y., Zhang, X., Lai, Y., Li, L., Wang, F., Shang, J., & Zha, X. (2024). Targeting Periplakin of Novel Benzenesulfonamides as Highly Selective Agonists for the Treatment of Vitiligo. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01717

Vancouver

Zhong H, Li P, Yan Q, Xia Y, Zhang X, Lai Y, et al. Targeting Periplakin of Novel Benzenesulfonamides as Highly Selective Agonists for the Treatment of Vitiligo. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01717

BibTeX
@article{Zhong2024,
  author = {Zhong, Hui and Li, Panpan and Yan, Qiuming and Xia, Yu and Zhang, Xin and Lai, Yifan and Li, Liqiang and Wang, Feifei and Shang, Jing and Zha, Xiaoming},
  title = {Targeting Periplakin of Novel Benzenesulfonamides as Highly Selective Agonists for the Treatment of Vitiligo},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01717}
}
Kostenlos starten →